• Contact
  • Imprint
  • Privacy
  • Links
  • Login
Business Chemistry
  • About Us
    • Aim and Scope
    • Why publish
    • Our Partners
    • Editorial Board
    • Contact
  • Issues
  • Articles
  • For Authors
    • Editorial Policies
    • Submission Guidelines
    • Call for Papers
    • Copyright and Disclaimer
  • For Readers
Select Page

VUCCA is the new VUCA world

by | Jun 2020

While identifying relevant trends for the chemical industry at the start of the last issue, we were not expecting that in the following months the world would become overwhelmed by a completely new topic. Now just four months later, one cannot imagine devising a...

Combine or combust? – Circular economy, digitalization and collaboration models for the new chemical industry 4.0

by | Jun 2020

Abstract The chemical-pharmaceutical industry, like other industrial sectors, is facing transformative changes exemplified by ‘Industry 4.0’ – including digitalization, circular economy approaches, and other innovations impacting its business model. These changes also...

How to evaluate the future business potential of innovation fields in the chemical industry

by | Jun 2020

Abstract Decisions about the further development or termination of innovation fields (IF) have a high relevance for companies. However, due to a lack of information in the front end of innovation (FEI) as well as missing evaluation methods and criteria, selection...

Sustainability as a criterion for business models – A framework for the life science sector

by | Jun 2020

Abstract The research discourse on sustainability and on business models can be described as diverse in approaches and understanding of subject areas. The value-oriented business model and the twenty criteria of the German Sustainability Code represent a sample which...

Wealth effects of corporate spin-offs – An event study analysis of the chemical & pharmaceutical industry

by | Jun 2020

Abstract The present article studies wealth effects of global spin-off announcements of the chemical and pharmaceutical industry that were announced between January 2001 and October 2019. The cumulative average abnormal return over the 3-day event window is 3.91%....
« Older Entries
Next Entries »

You are currently viewing a placeholder content from Mailjet Newsletter. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

Unblock content Accept required service and unblock content
More Information '
'

Newsletter
Subscription

  • Follow